Guerbet LLC

USA

Related Content

Technology | March 22, 2013
FDA Approves First Macrocyclic and Ionic Gadolinium-Contrast Agent for MRI
Guerbet announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine), a...
read more
Dotarem Guebert LLC FDA NDA Approval Contrast Media MRI Systems
News | February 20, 2013
FDA Committee Recommends Approval of Guerbet’s Macrocyclic, Ionic Gadolinium MRI Contrast Agent
Guerbet announced that the Medical Imaging Drugs Advisory Committee to U.S. Food and Drug Administration (FDA) has...
read more
Technology | October 28, 2008
Oxilan Offers Contrast Media for Peripheral Procedures
Oxilan (Ioxilan Injection) is a contrast media for use in peripheral procedures because of its viscosity. Its reported...
read more
Technology | November 14, 2007
Contrast Agent Lowers Side Effects
Guerbet will feature its Oxilan (ioxilan) injection, a contrast agent that is a nonionic low-viscous and low-osmolar
read more
News | October 17, 2007
Guerbet Highlights X-Ray Agent, Oxilan
October 18, 2007 - Guerbet will feature at TCT 2007 its x-ray contrast agent, Oxilan (ioxilan) injection, a contrast
read more
Technology | September 05, 2007
Guerbet’s Oxilan Wins Frost & Sullivan Award for Contrast Media with Low Side Effects
Guerbet’s flagship X-ray contrast agent, Oxilan (ioxilan) injection, is a contrast agent that is a nonionic, low-visc
read more
Technology | August 29, 2006
OXILAN Offers Contrast Media for Peripheral Procedures
OXILAN (Ioxilan Injection) is a contrast media for use in peripheral procedures because of its viscosity.
read more
© Copyright Scranton Gillette Communications. All Rights Reserved.
Overlay Init